19. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenues

The Company’s portfolio of marketed products, with the majority of sales from Targadox®, Ximino®, and Exelderm®. Substantially all of the Company’s product revenues are recorded in the U.S. Substantially all of the Company’s collaboration revenues are from its collaboration with TGTX. Revenues by product and collaborator are summarized as follows:

Significant Customers

Commencing in the second quarter of 2018, the majority of our dermatology products are sold under a third-party logistics (“3PL”) Title Model, and as such, one customer consistently accounts for a significant portion of gross product revenue and AR.  Under a 3PL Title Model, the company sells product to a 3PL, who in turn, manages distribution and collections. 

For the three and nine months ended September 30, 2019, gross product revenue under the 3PL Title Model accounted for approximately 60.0% and 76.0%, respectively.

For the three months ended September 30, 2018, one of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total gross product revenue in the amount of $10.9 million.

For the nine months ended September 30, 2018, two of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total gross product revenue in the amount of $22.5 million and $7.3 million, respectively.

At September 30, 2019, two of the Company’s Dermatology Products customers accounted for more than 10.0% of its total accounts receivable balance in the amounts of $3.5 million and $2.8 million.

At September 30, 2018, two of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $9.0 million and $1.4 million, respectively.